SHANGHAI YIZHONG(SH:688091) Cai Jing Wang·2025-10-30 06:10Core Viewpoint - Shanghai Yizhong reported significant growth in both revenue and net profit for the third quarter of 2025, driven primarily by the strong sales of its core product, paclitaxel micelles [1] Financial Performance - The company's total revenue for the first three quarters of 2025 reached 243 million yuan, representing a year-on-year increase of 43.4% [1] - The net profit attributable to shareholders was 50.66 million yuan, up 46.1% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 48.29 million yuan, reflecting a 55.4% increase compared to the previous year [1] - The operating cash flow net amount was -21.42 million yuan, a decline of 202.7% year-on-year [1] - The earnings per share (EPS) on a fully diluted basis was 0.2451 yuan [1] Quarterly Highlights - In the third quarter, the company achieved a revenue of 82.82 million yuan, marking a 73.7% increase year-on-year [1] - The net profit attributable to shareholders for the third quarter was 12.65 million yuan, a remarkable increase of 7751.8% year-on-year [1] - The net profit after deducting non-recurring gains and losses turned around from a loss of 2.08 million yuan in the same period last year to a profit of 11.24 million yuan [1] - The EPS for the third quarter was 0.0612 yuan [1] Product Performance - The sales volume of the core product, paclitaxel micelles, increased by 682% compared to the same period last year, significantly contributing to the growth in revenue and total profit [1] - The company's research and development investment rose to 25.74 million yuan, accounting for 31.08% of total revenue [1]